Why Drug Prices Are Lower in China: Procurement, Generic Quality, and Four Major Drug Categories

This guide is written for three kinds of readers: foreigners who suspect "cheap Chinese drugs" means "low quality"; people planning medical tourism who want to know what they can legally take home; and long-term expats, students, or nomads in China who need ongoing prescription medication.

What you'll get: why drug prices are low in China, how generic drug quality is tiered, and where the legal line sits for taking drugs back home.

Why drugs are cheap in China: the national procurement mechanism

International readers often misread Chinese drug pricing. Originator drugs (still under patent) typically cost the same in China as in the US or Europe, sometimes more, because pricing power stays with the multinational pharma company. What's cheap is the off-patent generic version, and the core reason isn't lower quality. It's national centralized drug procurement (集采, jí cǎi), run by the National Healthcare Security Administration (NHSA).

集采 isn't ordinary negotiation. The state uses 80%+ of public hospital purchase volume as leverage, with a "winning bid = guaranteed coverage" mechanism, to compress off-patent drug prices. Mechanism-driven price drops typically range from 50% to 95%.

How 集采 works

Since the "4+7 pilot" in November 2018, the NHSA has run 11 procurement rounds covering over 600 drugs. The logic is straightforward:

• The National Joint Procurement Office publishes the list of drugs to be procured (classified by International Nonproprietary Name, or INN)
• Domestic and international generic manufacturers bid, submitting their lowest price
• Winning manufacturers (usually 1 to 10 per drug) commit to supply guarantees
• Public hospitals, via the medical insurance system, must prioritize the winning bidder and meet a committed volume (typically 60% to 80% of total demand for that drug)

This mechanism trades "certain sales volume" for "certain low price." For manufacturers, it's scale-for-margin. For patients, it's price-for-access. The cost is that winning manufacturers must maintain quality (any GMP violation can get them delisted), and originator pharma loses public-hospital market share (though they keep private and retail channels).

How big is the price gap

Below are several documented examples (NHSA public data is the source of record; specific bid prices follow official round publications):

Data is cross-verified from NHSA procurement announcements (2018-2024), the IQVIA Institute Global Drug Pricing Report 2024, the GoodRx Drug Price Database, and the NHS BSA published price list 2024-25. Specific bid prices follow the official NHSA round announcements; individual purchase prices vary slightly by city, insurance status, and pharmacy type.

How to read the "5x to 50x cheaper" headline:

• It is not a quality discount. It's pricing power released by procurement scale
• US retail prices are high mainly because of the PBM (pharmacy benefit manager) chain and insurance-intermediary margins, not the underlying cost of the drug
• UK NHS prices are low because of state negotiation plus reimbursement structure, which is structurally similar to China's 集采 mechanism
• For non-集采 originator drugs in China (such as newly launched on-patent therapies), prices are comparable to or higher than US/Europe. 集采 only compresses off-patent generics

If your question is "can I buy my medication cheaper in China," the first step is checking whether the INN is on the procurement list; the second is checking whether you can access public-hospital or insurance-platform channels (foreigners usually pay out of pocket); and only then does the price itself come into play.

How 集采 prices are set: process and one case study

A case study: Imatinib

Imatinib is an oral targeted therapy for chronic myeloid leukemia and a first-line treatment in both Chinese and international clinical guidelines. The originator product, Glivec (Chinese brand: 格列卫), was developed by Novartis.

Before the China patent expired in 2013, originator Glivec retailed for around RMB 24,000 per box (30-day supply) in China. After expiry, domestic generics (such as Jiangsu Hansoh's "Xinwei" / 昕维) launched at RMB 6,000-8,000. But the real price cliff happened after the December 2018 "4+7" procurement round: Hansoh's generic bid price fell to RMB 600-800 per box, and after the third procurement round in 2020 it dropped further to roughly RMB 200-500. Over the same period, originator Glivec, having lost its public-hospital volume, adjusted down to around RMB 7,000-12,000 per box.

This case illustrates three things:

First, the price gap is not because Chinese generics are lower quality. Hansoh's Xinwei and multiple other generic versions have all passed the national consistency evaluation (more on this in the next section), with publicly accessible bioequivalence data.

Second, originator pharma hasn't fully withdrawn from China, but the market share has shifted from public hospitals to private hospitals, self-pay pharmacies, and high-end international medical departments. In JCI-accredited international hospital units, originator Glivec remains a common option.

Third, cross-border patients need to be clear about which channel they're buying through. A public hospital with insurance (foreigners self-pay but still get the procurement price) gets you RMB 200-500 per box; a JCI international department or private pharmacy offering the originator is still RMB 7,000-12,000; retail pharmacies outside the insurance channel sit somewhere in between.

Similar price cliffs have appeared across more than a dozen common chronic-disease drugs: atorvastatin (lipid control), valsartan (blood pressure), metformin (diabetes), omeprazole (acid reflux), montelukast (asthma), and others.

Generic drug quality: a three-tier system and how to choose

Chinese generics are not a homogeneous group. Since 2016 the National Medical Products Administration (NMPA) has been running the "Generic Drug Consistency Evaluation," which effectively splits generics into three tiers. Understanding the tiers is how you decide whether the cheap version is the right one for you.

The three tiers explained

Tier 1: Originator drug

Produced by the original patent holder or its licensee. Full clinical trial data; bioavailability backed by the original dossier. In China this is still the preferred option in private hospitals, JCI international departments, and most multinational direct-billing insurance lists. Highest price, most consistent quality, and the gold standard.

Tier 2: Generic with consistency evaluation passed

Produced by domestic generic manufacturers that have passed the NMPA-led bioequivalence trial and quality consistency evaluation. The evaluation covers: pharmaceutical consistency (active ingredient sourcing, excipients, manufacturing process), in-vitro dissolution profiles, and in-vivo bioequivalence trials (peak concentration Cmax and exposure AUC compared to the originator in healthy volunteers, with a ±20% allowance band).

A generic that passes consistency evaluation is regulatorily deemed to have "the same clinical efficacy and safety" as the originator. Winning bidders in the 集采 list are essentially all in this tier (consistency evaluation is a precondition for procurement participation).

Tier 3: Older generics that haven't passed consistency evaluation

Generic versions approved before consistency evaluation began in 2016. Most have already exited the main public-hospital channel. National policy is clear: from 2025 onward, generics that haven't passed consistency evaluation will be phased out of production and sale (the exact timeline varies by drug). This is the tier you should avoid.

How to tell which tier your drug is in

The most direct method: check the National Medical Products Administration (NMPA) website under "Generic Drug Consistency Evaluation Public Disclosure," and search by drug name or approval number. Products that have passed will be marked as "passed" or "deemed passed."

Practical shortcuts:

• 集采 winning drugs and drugs on the medical insurance platform list → typically Tier 2 (consistency evaluation passed)
• Drugs prescribed in JCI international departments or appearing on multinational direct-billing insurance lists → typically Tier 1 (originator)
• Drugs from a non-chain street-corner pharmacy, or loose pills priced far below market → high risk; could be Tier 3 or counterfeit

When to insist on the originator

For most common chronic-disease drugs, a Tier 2 generic with consistency evaluation is a reasonable choice. But there are three situations where we recommend the originator:

1. Narrow therapeutic index drugs (such as warfarin, levothyroxine, digoxin, antiepileptics): the dose-response curve is steep, and small bioavailability differences can have clinical impact.
2. Complex biologics (such as insulin analogues, monoclonal antibodies, biosimilars): molecular structure is complex, and equivalence is harder to evaluate than for small molecules.
3. Stable chronic-disease patients switching brands: if you've been stable on a particular brand for years with well-controlled markers, there's no need to switch for a price gap; if you do switch, monitor more closely during the transition.

Final decisions in these three situations rest with you and your physician or pharmacist.

Price examples across 4 common drug categories

Below are price comparisons across four high-frequency drug categories, with 2 representative drugs per category (INN + Chinese name + brand name). Prices follow the dates and sources listed in each table; individual purchase prices vary by city, insurance status, and pharmacy type.

The three price points (China 集采 / US GoodRx retail median / UK NHS reimbursement) reflect market structure differences (PBM chain / state negotiation / bulk procurement), not a quality discount on Chinese drugs.

Hypertension: Valsartan + Amlodipine

Diabetes: Metformin + Insulin glargine

Antibiotics: Cefuroxime axetil + Amoxicillin

Antibiotic note: antibiotics are prescription-only in China, and regulation has tightened in recent years (it's very hard to obtain loose antibiotics outside a hospital with a prescription). Given global antimicrobial resistance concerns, this guide does not encourage stockpiling antibiotics to take home.

Oncology: Imatinib + Gefitinib

Oncology note: targeted therapy regimens, dosing, and monitoring vary across clinical guidelines. Even if the price is a strong motivator, the clinical decisions (which targeted drug, dose adjustments, combination therapy, side-effect management) must be led by your oncologist. This guide does not substitute for clinical judgement.

How to actually buy these drugs in China

Once you understand the previous three sections (集采, generic tiers, and the four-category pricing), the next step is turning those prices into "where I can actually get this drug, and at what price." Distribution channels in China matter as much as the headline price, sometimes more.

Public hospitals: this is where the 集采 winning drugs sit. After registration and a doctor's prescription, you collect the drug at the in-hospital pharmacy, priced at the procurement bid price plus a max 5% mark-up (many provinces have eliminated the mark-up entirely). Foreigners typically pay out of pocket, but you still get the procurement price; no insurance enrolment is required.

JCI international hospitals and international departments: the main route for originator drugs. Prices are 5-10x higher than public hospitals, but stock is consistent and most multinational insurance plans direct-bill. If your regimen specifically calls for the originator, or your doctor insists you stay on a particular brand, this is the path.

Private hospitals and licensed retail pharmacies: somewhere in between. Tier-2 generics plus some originator. Prescription drugs require a doctor's prescription; over-the-counter (OTC) items can be self-purchased.

Channels to avoid entirely: non-chain street-corner pharmacies, QR-code-to-WeChat resellers, cross-border online platforms, and social-media sourcing. The biggest risk in these channels isn't legal, it's quality — sourcing, storage, and counterfeit status are all unverifiable.

Prescription and purchase flow

Regardless of channel, prescription drugs require a Chinese-language prescription written by a licensed-to-prescribe physician inside China (some international departments issue bilingual prescriptions). If you already have an overseas prescription and want to use the same INN locally:

• Register at a JCI international hospital or an international department in China, have a local physician review your overseas prescription and medical records, and issue a local prescription; registration fee RMB 200-1,500, consultation fee separate; this is the compliant path
• Public hospitals' international departments offer a similar flow at typically lower cost (registration RMB 50-300), with Chinese and English as the working languages
• Most JCI 24-hour clinics with in-house pharmacies can evaluate and dispense on the same day (see FAQ on urgent-medication access)

Common questions

Q: I have an overseas prescription. Can I just take it to a Chinese pharmacy?

A: No. Chinese pharmacies and hospitals only accept prescriptions written by physicians licensed to prescribe inside China. However, you can use the compliant "overseas prescription + medical records review + local prescription" bridge at a JCI international hospital, a public hospital's international department, or a private international medical center (see previous section).

Q: I need a drug urgently — say, I need to refill something on my first day in China. What do I do?

A: Beijing United Family, Shanghai United Family, and Shanghai Jiahui (among other JCI international hospitals) typically operate 24-hour clinics with on-site pharmacies. Most can issue same-INN Chinese local drugs based on your foreign prescription plus an on-site physician's evaluation, with self-pay options. Costs: registration plus the drug itself, paid out of pocket; multinational insurance typically reimburses after payment (see insurance-use).

Q: How much do originator drugs and consistency-evaluation-passed generics actually differ clinically?

A: At the regulatory level, they are considered to have "the same clinical efficacy and safety," based on in-vitro dissolution profiles plus in-vivo bioequivalence trials (peak concentration and exposure compared to the originator in healthy volunteers, within a ±20% band). For most common chronic-disease drugs, there is no measurable clinical-outcome difference between the generic and the originator. There are three exceptions where the originator should be preferred: narrow therapeutic index drugs (warfarin, levothyroxine, antiepileptics, etc.); complex biologics (insulin analogues, monoclonal antibodies); and stable chronic-disease patients switching brands (years of stability on one brand and well-controlled markers — no reason to switch for the price gap). Final decisions rest with you and your physician or pharmacist.

Q: What are the common pitfalls for foreigners buying drugs in China?

A: Three are common. First, channel confusion — mixing up street-corner pharmacies with licensed retail pharmacies, where quality risk is high. Second, treating prescription drugs as OTC — some products marketed as "health supplements" are actually prescription drugs, and side-effects go unmonitored. Third, confusing the insurance-platform price with the retail price — foreigners self-paying through the public-hospital channel get the procurement (mechanism) price, but some travelers, after being quoted the "insurance price," try to buy a non-prescription drug at the same price at a retail pharmacy and find it costs more. Retail mark-ups differ across channels.

Q: What are the exact rules for taking drugs across the border back home?

A: This is a separate topic (your home country, drug classification, quantity, prescription, original packaging, and declaration threshold all have different rules) and will be covered in a dedicated guide. Until then, three universal reminders: keep the original packaging, prepare an English-language prescription (with INN, dose, and treatment duration), and check your destination country's official customs page before departure — don't rely on second-hand travel advice, as rules change every year.

How WellChina helps

WellChina's job, when you're making drug-related decisions, is to give you a neutral second opinion plus China-side channel verification — so you don't have to rely on a reseller's promise, and you don't have to read the NHSA procurement catalogue and NMPA consistency evaluation database yourself.

What we do:

• Check whether your target drug is on the NHSA procurement list and has passed consistency evaluation
• Help you find a compliant in-China purchasing channel by INN (public hospital international department / JCI / licensed pharmacy)
• Help you prepare the compliant bridge from an overseas prescription to a local Chinese prescription (which JCI accepts what, registration cost, bilingual prescription issuance)
• Post-trip doctor-to-doctor records handoff (Chinese attending physician → your family doctor at home)

What we don't do: drug resale (we don't sell drugs); medical judgement (dosing, brand-switching, and side-effect management are your physician's responsibility); brand-specific recommendations (discuss with your physician or pharmacist).

Three service tiers

Self-check Consult (USD $29): a 60-minute video consultation plus an INN mapping table (your target drug → equivalent Chinese generic / originator + 集采 list status). Suitable if you can run the process yourself but want a professional second opinion.

Coordination Service (USD $59): everything in Self-check Consult, plus China-side compliant channel verification for your target drug (which JCI hospital / which pharmacy / consultation and registration pathway), plus bilingual prescription preparation guidance. Suitable for complex regimens or multi-drug trips.

Full Concierge (from USD $129): everything in Coordination Service, plus post-trip doctor-to-doctor records handoff (English-language summary from your Chinese attending physician + medication list + imaging / labs + prescription recommendations, handed off to your family doctor at home). Suitable when the patient can't coordinate multiple channels alone, or when medium-to-long-term medication continuity matters.

View service plans → · Tell us about your trip →

---

Sources cross-verified 2026-05-14: NHSA 11 rounds of procurement public announcements 2018-2024; NMPA Generic Drug Consistency Evaluation public disclosure; WHO INN database; IQVIA Institute global drug pricing reports 2024; GoodRx Drug Price Database 2025; NHS BSA Published Drug Tariff 2024-25. Last reviewed 2026-05-14; next review 2026-08-14. Cross-border drug import customs rules are out of scope for this guide and will be covered separately.

Disclosure: WellChina is not a pharmacy, does not hold a license to sell drugs, and does not accept commissions from any pharma company or pharmacy. Service plan fees only cover our coordination time. All clinical decisions (which drug, dosing, switching brand or generic, drug interaction assessment) must be made jointly by you and a licensed physician or pharmacist.

— WellChina editorial team